Bioimagene Launches; Introduces an Innovative Solution to Enable Digital Pathology
A large amount of valuable life sciences data used by researchers and medical professionals is in the form of images. Life sciences researchers, pathologists and radiologists are spending an even larger amount of time every day analyzing these images for R&D and diagnosis in a laborious manual process.
With 700 new drug targets under discovery and more than 2.9 million confirmed cancer cases per year, hundreds of millions of slides are to be analyzed annually. The current process is completely manual and lacks in efficiency, speed and accuracy leading to annual costs of billions of dollars for analysis, research and diagnosis.
Bioimagene has launched to address this multi-billion dollar opportunity to enable digital. With Bioimagene’s suite of products, industry professionals will be empowered to:
— analyze the glass slides more accurately, assisted by a robust image analysis rules engine
— analyze slides anytime, anywhere via a web-based hosted application
— share their analysis with fellow pathologists
— provide second opinions rapidly without delay
— provide diagnostic and research conclusions much faster
— store and build a centralized reference library of slides and cases with complete analysis for future reference
Bioimagene’s offering consists of a set of bio-image analysis products built on iHarness, its patent-pending technology platform that combines image analysis and pathological heuristics to provide a rapid research and diagnosis framework. Research organizations as well as pathology labs can expect millions of dollars in saved costs every year by leveraging virtual digital pathology, enabled by iHarness.
Funded by prominent investors and led by a strong management team, Bioimagene has also assembled a stellar board of advisors consisting of experts from the medical, pathology and imaging technology fields. “Pathology labs and research centers will see the drastic improvement in their capabilities using our suite of products and we believe that this will shave billions of dollars of costs from the current processes,” said Nagesh Mhatre, Bioimagene’s Chairman and a veteran in the biotech and bio-informatics industry.
“We see a big opportunity to provide a new generation of image informatics products to truly enable digital pathology that will drastically improve pathological research and diagnostics delivering speed, efficiency and tremendous cost savings to the industry,” said Bioimagene Chief Executive Officer Mohan Uttarwar.
About Bioimagene
Pathologists and life sciences researchers are inundated with valuable data in the form of glass slides. The current pathological analysis process is completely manual and causes time and cost efficiencies leading to millions of dollars of expenditures associated with just slide analysis, diagnosis and second opinions.
Bioimagene is focused on eliminating this highly inefficient and laborious pathological analysis process. Bioimagene provides sophisticated bio-image analysis products built on iHarness, its patent-pending technology platform that combines image analysis and pathological heuristics to provide a rapid research and diagnosis framework. These products are aimed at empowering pathologists with truly virtual and digital pathological analysis. Pathologists and researchers will be able to analyze, store and share images to deliver quicker and more accurate diagnosis. With its scalable digital pathology solution, the industry is expected to save millions of dollars in saved costs.
Bioimagene is headquartered in Cupertino, California, with its development center in Pune, India. For more information on Bioimagene, visit the company’s web site at www.bioimagene.com .
